Akers Biosciences Reports Earnings for Fiscal Year 2017

NEXT STORY
Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML)
PREV STORY
Lexicon Pharmaceuticals to Highlight Pipeline Progress at R&d Day on April 10, 2018
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca

author_avatar
NASDAQ Market News

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

author_avatar
NASDAQ Market News

Orthopedic Devices Market to Reach USD 71.67 Billion by 2026; Increasing Geriatric Population to Boost Growth, says Fortune Business Insights™

author_avatar
NASDAQ Market News